ADMA Biologics ADMA Interest Expense, Nonoperating
Interest Expense, Nonoperating at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's interest expense, nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's interest expense, nonoperating?
- ADMA Biologics (ADMA) reported interest expense, nonoperating of $2.1M in Q1 2026.
- How has ADMA Biologics's interest expense, nonoperating changed year-over-year?
- ADMA Biologics's interest expense, nonoperating increased by 6.3% year-over-year, from $1.98M to $2.1M.
- What is the long-term trend for ADMA Biologics's interest expense, nonoperating?
- Over 2 years (2023 to 2025), ADMA Biologics's interest expense, nonoperating has grown at a -46.7% compound annual growth rate (CAGR), from $25.03M to $7.11M.
- What does interest expense, nonoperating mean?
- Reflects the costs incurred by a company for borrowed funds, such as interest on debt obligations. High levels of this expense relative to operating income can signal financial risk and leverage constraints.